LIVE VIRTUAL CME ACTIVITY
Assessing Progress in FSHD Treatment Options: Unravelling Challenges and Measuring Outcomes
Wednesday, October 16, 2024
11:45am – 12:45pm EDT
Join Leo Wang and Maya Hatch for an insightful journey into the world of Facioscapulohumeral Muscle Dystrophy (FSHD)
The session will cover its etiology, clinical presentations, and the complexities of assessing treatment outcomes in clinical trials. Key focuses include the innovative Reachable Workspace (RWS) metric for functional assessment, the impact of current clinical trials, and emerging therapeutic targets. Discussions will also highlight biomarker insights, disease mechanisms like DUX4 regulation, and future strategies for FSHD management. Don’t miss this opportunity to gain insights from experts shaping the future of FSHD research and care, along with perspective from a real-world patient living with FSHD.
This activity is supported by an educational grant from Fulcrum Therapeutics.
This activity will be held during the AANEM Annual Meeting. It is not part of the official scientific program of the AANEM.
Register for the Free Virtual Session
Earn up to 1.0 AMA PRA Category 1 Credit™
Faculty
Leo H. Wang, MD, PhD
Professor of Neurology
University of Washington, Seattle Wellstone Center, Seattle, WA
Maya N. Hatch, PhD
Clinical Researcher
Department of Physical Medicine & Rehabilitation at the University of California, Irvine Irvine, CA
Reserve your free virtual seat now!
Agenda
- Introduction to Facioscapulohumeral Muscle Dystrophy (FSHD)
- Understanding FSHD: Etiology and Epidemiology
- Exploring Clinical Presentations in FSHD
- Challenges in Assessing Clinical Outcomes in FSHD Trials
- Reliable Outcome Measures for FSHD Trials: Focus on Reachable Workspace (RWS)
- Trials in FSHD
- Mechanism of Disease and Emerging Therapeutic Targets
- Conclusion and Future Perspectives on FSHD Management Strategies